Full Opioid Agonists

Opioid Agonist

Pain, Postoperative

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-11"></a><h1>11 DESCRIPTION</h1>XTAMPZA ER (oxycodone) extended-release capsules are an opioid agonist for oral use. The capsules contain microspheres formulated with oxycodone base and are supplied in strengths of 9 mg (equivalent to 10 mg oxycodone HCl), 13.5 mg (equivalent to 15 mg oxycodone HCl), 18 mg (equivalent to 20 mg oxycodone HCl), 27 mg (equivalent to 30 mg oxycodone HCl), and 36 mg (equivalent to 40 mg oxycodone HCl) capsules. The capsule strengths describe the amount of oxycodone base per capsule. The structural formula for oxycodone is as follows:<img alt="Chemical Structure" src="xtampza-02.jpg"/>C18H21NO4                    MW 315.37 g/molThe chemical name is 4,5 α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one.Oxycodone base is a white, odorless crystalline powder derived from the opium alkaloid, thebaine. Oxycodone is present as myristate salt in the XTAMPZA ER formulation.Each XTAMPZA ER capsule contains either 9, 13.5, 18, 27, or 36 mg of oxycodone (equivalent to 10, 15, 20, 30, or 40 mg of oxycodone HCl, respectively) and the following inactive ingredients: myristic acid, yellow beeswax, carnauba wax, stearoyl polyoxyl-32 glycerides, magnesium stearate, and colloidal silicon dioxide. The capsule shells collectively contain titanium dioxide, hypromellose, and water. Additionally, the 9 mg and 18 mg strength capsule shells contain yellow iron oxide, the 13.5 and 36 mg strength capsule shells contain red iron oxide, and the 27 mg strength capsule shells contain black iron oxide.</section>

XTAMPZA

Abuse-Deterrent 12 HR oxycodone 9 MG Extended Release Oral Capsule

Xtampza

Abuse-Deterrent 12 HR oxycodone 9 MG Extended Release Oral Capsule [Xtampza]

Abuse-Deterrent 12 HR oxycodone 13.5 MG Extended Release Oral Capsule

Abuse-Deterrent 12 HR oxycodone 13.5 MG Extended Release Oral Capsule [Xtampza]

Abuse-Deterrent 12 HR oxycodone 18 MG Extended Release Oral Capsule

Abuse-Deterrent 12 HR oxycodone 18 MG Extended Release Oral Capsule [Xtampza]

Abuse-Deterrent 12 HR oxycodone 27 MG Extended Release Oral Capsule

Abuse-Deterrent 12 HR oxycodone 27 MG Extended Release Oral Capsule [Xtampza]

Abuse-Deterrent 12 HR oxycodone 36 MG Extended Release Oral Capsule

Abuse-Deterrent 12 HR oxycodone 36 MG Extended Release Oral Capsule [Xtampza]

oxycodone

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information 

Medication Guide 

Pharmacy List 

Formulary Information 

Coverage Authorization Request 

Coverage Authorization Appeals 

Enroll in Patient Savings Program 

Other HCP Resources 

About Xtampza ER 

Taking Xtampa ER 

FAQs: Pain Management 

Patient Resources 

Instructions For Use: Pain Management 

Patient Brochure 

Transitioning From Oxycontin to Xtampa ER Brochure 